HK1117524A1 - Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine - Google Patents

Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine

Info

Publication number
HK1117524A1
HK1117524A1 HK08108277.9A HK08108277A HK1117524A1 HK 1117524 A1 HK1117524 A1 HK 1117524A1 HK 08108277 A HK08108277 A HK 08108277A HK 1117524 A1 HK1117524 A1 HK 1117524A1
Authority
HK
Hong Kong
Prior art keywords
syntesis
benzeneamine
imidazol
methyl
tri fluorome
Prior art date
Application number
HK08108277.9A
Other languages
English (en)
Inventor
Joseph Mckenna
Wen-Chung Shieh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1117524A1 publication Critical patent/HK1117524A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
HK08108277.9A 2005-06-09 2008-07-25 Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine HK1117524A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US70559005P 2005-08-04 2005-08-04
PCT/US2006/022155 WO2006135641A2 (en) 2005-06-09 2006-06-07 PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE

Publications (1)

Publication Number Publication Date
HK1117524A1 true HK1117524A1 (en) 2009-01-16

Family

ID=37091153

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08108277.9A HK1117524A1 (en) 2005-06-09 2008-07-25 Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine

Country Status (32)

Country Link
US (2) US8124763B2 (xx)
EP (1) EP1924574B1 (xx)
JP (1) JP5118024B2 (xx)
KR (3) KR101514593B1 (xx)
AR (1) AR053890A1 (xx)
AT (1) ATE487709T1 (xx)
AU (1) AU2006258051B2 (xx)
BR (1) BRPI0611663A2 (xx)
CA (1) CA2610105C (xx)
CY (1) CY1111428T1 (xx)
DE (1) DE602006018156D1 (xx)
DK (1) DK1924574T3 (xx)
EC (1) ECSP077982A (xx)
EG (1) EG25039A (xx)
GT (1) GT200600217A (xx)
HK (1) HK1117524A1 (xx)
IL (1) IL187421A (xx)
JO (1) JO2636B1 (xx)
MA (1) MA29599B1 (xx)
MX (1) MX2007015423A (xx)
MY (1) MY147436A (xx)
NO (1) NO340743B1 (xx)
NZ (1) NZ563740A (xx)
PE (1) PE20070015A1 (xx)
PL (1) PL1924574T3 (xx)
PT (1) PT1924574E (xx)
RU (1) RU2444520C2 (xx)
SA (1) SA06270147B1 (xx)
SI (1) SI1924574T1 (xx)
TN (1) TNSN07463A1 (xx)
TW (1) TWI430999B (xx)
WO (1) WO2006135641A2 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
ES2394258T3 (es) 2008-11-05 2013-01-30 Teva Pharmaceutical Industries Ltd. Formas cristalinas de Nilotinib HCL
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
MX2013010977A (es) 2011-03-31 2013-10-30 Procter & Gamble Sistema, modelos y metodos para identificar y evaluar agentes dermoactivos eficaces para tratar la caspa/dermatitis seborreica.
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
EP2859486A2 (en) 2012-06-06 2015-04-15 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
CN103694176B (zh) 2014-01-07 2015-02-18 苏州立新制药有限公司 尼洛替尼中间体的制备方法
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
WO2019152977A2 (en) 2018-02-05 2019-08-08 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
AU5539294A (en) 1992-12-24 1994-07-19 Hemagen/Pfc Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
PT1044977E (pt) 1999-03-09 2002-09-30 Sigma Tau Ind Farmaceuti Derivados de camptotecina com actividade antitumoral
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DE19926056B4 (de) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
JP2005508354A (ja) 2001-10-15 2005-03-31 クリチテック インコーポレーテッド 水に溶けにくい薬物の送込み用組成物および方法並びに治療方法
WO2003057128A2 (en) 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
FR2840303B1 (fr) 2002-05-31 2005-07-15 Rhodia Chimie Sa Procede d'arylation ou de vinylation ou d'alcylynation d'un compose nucleophile
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
WO2005060871A1 (en) 2003-12-17 2005-07-07 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
EP1924574A2 (en) 2008-05-28
PE20070015A1 (es) 2007-02-06
CA2610105A1 (en) 2006-12-21
GT200600217A (es) 2007-03-28
AU2006258051B2 (en) 2010-09-09
JP5118024B2 (ja) 2013-01-16
TWI430999B (zh) 2014-03-21
MA29599B1 (fr) 2008-07-01
CY1111428T1 (el) 2015-08-05
WO2006135641A2 (en) 2006-12-21
JO2636B1 (en) 2012-06-17
DE602006018156D1 (de) 2010-12-23
TNSN07463A1 (en) 2009-03-17
MY147436A (en) 2012-12-14
KR20120066067A (ko) 2012-06-21
RU2007148231A (ru) 2009-07-20
US20080188656A1 (en) 2008-08-07
JP2008545786A (ja) 2008-12-18
KR101216249B1 (ko) 2012-12-28
EG25039A (en) 2011-07-06
US8124763B2 (en) 2012-02-28
KR101514593B1 (ko) 2015-04-22
US20120116081A1 (en) 2012-05-10
SI1924574T1 (sl) 2011-02-28
WO2006135641A3 (en) 2007-03-29
DK1924574T3 (da) 2011-02-14
AU2006258051A1 (en) 2006-12-21
IL187421A (en) 2011-11-30
NO340743B1 (no) 2017-06-12
KR20130118394A (ko) 2013-10-29
TW200726756A (en) 2007-07-16
NZ563740A (en) 2011-03-31
RU2444520C2 (ru) 2012-03-10
NO20080157L (no) 2008-01-09
AR053890A1 (es) 2007-05-23
ECSP077982A (es) 2008-01-23
US8946416B2 (en) 2015-02-03
EP1924574B1 (en) 2010-11-10
BRPI0611663A2 (pt) 2010-09-28
PT1924574E (pt) 2011-02-08
IL187421A0 (en) 2008-02-09
MX2007015423A (es) 2008-02-21
SA06270147B1 (ar) 2009-12-22
ATE487709T1 (de) 2010-11-15
PL1924574T3 (pl) 2011-04-29
CA2610105C (en) 2014-03-25
KR20080022093A (ko) 2008-03-10

Similar Documents

Publication Publication Date Title
HK1117524A1 (en) Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
PL1948615T3 (pl) Pochodne pirazolu przydatne w leczeniu chorób ginekologicznych
PL1743882T3 (pl) Sposób do produkcji izocyjanianów
ZA200704468B (en) Process for the stabilization of dusting surfaces
ZA200705130B (en) Process for the synthesis of azetidinones
IL185419A0 (en) Improved process for the synthesis of enantiomeric indanylamine derivatives
PL1896425T3 (pl) Sposób wytwarzania 5-(metylo-1H-1-ilo)-3-trifluorometylo)-benzenoaminy
EP1922345A4 (en) PROCESS FOR THE PREPARATION OF COPOLYMER-1
SI1807395T1 (sl) Proces za sintezo N-alkoksiaminov
IL177315A0 (en) Process for the preparation of substituted triazole compounds
EP1951709A4 (en) IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS IN THE TREATMENT OF ALZHEIMER'S DISEASE
IL183379A0 (en) Processes for the preparation of linezolid intermediate
ZA200804264B (en) Process for the preparation of ferri-succinylcasein
ZA200710389B (en) Process for the copolymerization of propylene
ZA200601910B (en) Process for the preparation of organosilances
IL182421A0 (en) Process for the preparation of pyrazoles
PL1937662T3 (pl) Sposób wytwarzania duloksetyny
GB0402262D0 (en) Process for the manufacture of organic compounds
ZA200800921B (en) Pyrazolone derivatives for the treatment of tuberculosis
SG121993A1 (en) Process for influencing the properties of combustion residue
HK1128287A1 (en) Process for the preparation of tryptase inhibitors
IL185076A0 (en) Process for the prepartion of enantiomerically pure 1-substituted-3-aminoalcohols
ZA200607540B (en) Process for the preparation of substituted triazole compounds
PL1940926T3 (pl) Sposób powlekania przedmiotów
IL178237A0 (en) Process for the preparation of rosiglitazone